Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel
Status:
Terminated
Trial end date:
2017-10-02
Target enrollment:
Participant gender:
Summary
Determine the safety, tolerability, maximum tolerated dose (MTD), and recommended Phase II
dose (RP2D) of BAY1161909 in combination with paclitaxel in subjects with advanced
malignancies.